{"id":"edaravone-dexborneol-sequential-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Edaravone is a free radical scavenger that protects neurons from oxidative damage, particularly in acute ischemic stroke. Dexborneol, a monoterpene alcohol, improves microcirculation and has anti-inflammatory properties. The sequential administration is designed to optimize neuroprotection by first reducing oxidative stress followed by improving cerebral perfusion and reducing secondary neuronal injury.","oneSentence":"Edaravone reduces oxidative stress and neuroinflammation while dexborneol enhances cerebral blood flow and neuroprotection in a sequential combination therapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:33.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"}]},"trialDetails":[{"nctId":"NCT06176781","phase":"PHASE3","title":"The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-12-28","conditions":"Subjects With Acute Ischemic Stroke","enrollment":880}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Edaravone Dexborneol Sequential Therapy","genericName":"Edaravone Dexborneol Sequential Therapy","companyName":"Simcere Pharmaceutical Co., Ltd","companyId":"simcere-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Edaravone reduces oxidative stress and neuroinflammation while dexborneol enhances cerebral blood flow and neuroprotection in a sequential combination therapy. Used for Acute ischemic stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}